The 91 references in paper N. Tsareva A., Н. Царева А. (2017) “Идиопатическая легочная артериальная гипертензия: современный подход к диагностике и лекарственной терапии // Idiopathic pulmonary arterial hypertension: current approach to diagnosis and pharmacological treatment” / spz:neicon:pulmonology:y:2017:i:2:p:216-231

1
GaliéN., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J.2009; 34 (6): 1219–1263. DOI: 10.1183/ 09031936. 00139009.
(check this in PDF content)
2
Чазова И.Е., Мартынюк Т.В., ред. Легочная гипертензия. М.: Практика; 2015.
(check this in PDF content)
3
Vachiery J.-L., Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension.Eur. Respir. Rev. 2012; 21 (126): 313–320. DOI: 10.1183/09059180. 00005412.
(check this in PDF content)
4
Chemla D., Castelain V., HervéP. et al. Haemodynamic evaluation of pulmonary hypertension.Eur. Respir. J.2002; 20 (5): 1314–1331. DOI: 10.1183/09031936.02.00068002.
(check this in PDF content)
5
Benza R.L., Miller D.P., Gomberg-Maitland M. et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122 (2): 164–172. DOI: 10.1161/CIRCULATIONAHA.109.898122.
(check this in PDF content)
6
Badesch B.D., Champion H.C., Gomez-Sanchez M.A. et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.2009; 54 (30): S55–S56. DOI: 10.1016/ j.jacc.2009.04.011.
(check this in PDF content)
7
Berger R.M., Beghetti M., Humpl T. et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012; 379 (9815): 537–546. DOI: 10.1016/S0140-6736(11) 61621-8.
(check this in PDF content)
8
Trulock E., Edwards L., Taylor D. et al. Registry of the International Society for Heart and Lung Transplantation twenty fourth official adult lung and heart lung transplantation report 2007. J. Heart Lung Transplant.2007; 26 (8): 782–795. DOI: 10.1016/j.healun.2007.06.003.
(check this in PDF content)
9
Stehlik J., Edwards L.B., Kucheryavaya A.Y. et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report–2010.J. Heart Lung Transplant.2010; 29 (10): 1089– 1103. DOI: 10.1016/j.healun.2010.08.007.
(check this in PDF content)
10
Sitbon O., Morrell N.W. Pathways in pulmonary arterial hypertension: the future is here. Eur. Respir. Rev. 2012; 21 (126): 321–327. DOI: 10.1183/09059180.00004812.
(check this in PDF content)
11
Solomon J.J., Olson A.L., Fischer A. et al. Scleroderma lung disease.Eur. Respir. Rev.2013; 22 (127): 6–19. DOI: 10.1183/ 09059180.00005512.
(check this in PDF content)
12
Guazzi M., GaliéN. Pulmonary hypertension in left heart disease. Eur. Respir. Rev. 2012; 21 (126): 338–346. DOI: 10.1183/ 09059180.00004612.
(check this in PDF content)
13
Diller G.P., Dimopoulos K., Okonko D. et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005; 112 (8): 828–835. DOI: 10.1161/CIRCULATIONAHA.104.529800.
(check this in PDF content)
14
Peacock A.J., Murphy N.F., McMurray J.J.V. et al. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J.2007; 30 (1): 104–109. DOI: 10.1183/09031936. 0009 2306.
(check this in PDF content)
15
GaliéN., Palazzini M., Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur. Heart J. 2010; 31 (1): 2080–2086. DOI: 10.1093/eurheartj/ehq152.
(check this in PDF content)
16
Michelakis E.D. The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail. Rev. 2003; 8 (1): 5–21. DOI: 10.1023/A:1022150819223.
(check this in PDF content)
17
Rubin L.J., Simonneau G., Badesch D. et al. The study of risk in pulmonary arterial hypertension.Eur. Respir. Rev. 2012; 21 (125): 234–238. DOI: 10.1183/09059180. 00003712.
(check this in PDF content)
18
Humbert M., Souza R., Galie N. et al. Pulmonary arterial hypertension: bridging the present to the future.Eur. Respir. Rev.2012; 21 (126): 267–270. DOI: 10.1183/09059180. 00005312.
(check this in PDF content)
19
Simonneau G., Gatzolis G., Adatia I. et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.
(check this in PDF content)
20
3; 62 (25, Suppl.): D35–D41. DOI: 10.1016/j.jacc. 2013.10.029. 20. Humbert M., Sitbon O., Yaici A. et al. Survival in incident and prevalent cohort of patients with pulmonary arterial hypertension.Eur. Respir. J. 2010; 36 (3): 549–555. DOI: 10.1183/ 09031936.00057010.
(check this in PDF content)
21
GaliéN., Hoeper M., Torbicki A. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2009; 30 (20): 2493– 2537. DOI: 10.1093/eurheartj/ehr046.
(check this in PDF content)
22
Nickel N., Golpon H., Greer M. et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension.Eur. Respir. J.2012; 39 (3): 589–596. DOI: 10.1183/09031936.00092311.
(check this in PDF content)
23
Soubrier F., Chung W.K., Machado R. et al. Genetics and genomics of pulmonary arterial hypertension.J. Am. Coll. Cardiol. 2013; 62 (25, Suppl.): D13–D21. DOI: 10.1016/j.jacc. 2013.10.035.
(check this in PDF content)
24
Eyries M., Montani D., Girerd B. et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension.Nat. Genet. 2014; 46 (1): 65–69. DOI: 10.1038/ng.2844.
(check this in PDF content)
25
D’Alto M., Mahadevan V.S. Pulmonary arterial hypertension associated with congenital heart disease. Eur. Respir. Rev. 2012; 21(126): 328–337. DOI: 10.1183/09059180. 00004712.
(check this in PDF content)
26
Huang J.B., Liang J., Zhou L.Y. Eisenmenger Syndrome: Not Always Inoperable. Respir. Care.2012; 57 (9): 1488–1495. DOI: 10.4187/respcare.01418.
(check this in PDF content)
27
Rubin L.J. Primary pulmonary hypertension. Chest. 1993; 104 (1): 236–250.
(check this in PDF content)
28
Rubin L.J., Badesch D.B. Evaluation and management of the patient with pulmonary arterial hypertension. Ann. Intern. Med. 2005; 143 (4): 282–292. DOI: 10.7326/0003-4819-143-4200508160-00009.
(check this in PDF content)
29
GaliéN., Rubin L.J. Introduction: new insights into a challenging disease: A review of the third world symposium on pulmonary arterial hypertension. Am. Coll. Cardiol. J. 2004; 43 (12): S1. DOI: 10.1016/j.jacc.2004.03.003.
(check this in PDF content)
30
GaliéN., Torbicki A., Barst R. et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur. Heart. J. 2004; 25 (24): 2243–2278. DOI: 10.1016/ j.ehj.2004. 09.014.
(check this in PDF content)
31
Hambly N., Alawfi F., Mehta S. Pulmonary hypertension: diagnostic approach and optimal management. CMAJ. 2016; 188 (11): 804–812. DOI: 10.1503/cmaj.151075.
(check this in PDF content)
32
McLaughlin V.V., Archer S.L., Badesch D.B. et al. ACCF/ AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009; 119 (16): 2250–2294. DOI: 10.1161/CIRCULATIONAHA. 109.192230.
(check this in PDF content)
33
Чазова И.Е., Жданов В.С., Веселова С.П., Мареев В.Ю. Патология первичной легочной гипертензии. Архив патологии. 1993; (3): 52–55.0
(check this in PDF content)
34
Lowe B.S., Therrien J., Ionescu-Ittu R. et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes.J. Am. Coll. Cardiol. 2011; 58 (5): 538–546. DOI: 10.1016/j.jacc.2011.03.033.
(check this in PDF content)
35
Raymond R.J., Hinderliter A.L., Willis P.W. et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension.J. Am. Coll. Cardiol. 2002; 39 (7): 1214–1219.
(check this in PDF content)
36
Humbert M., Sitbon O., Chaouat A. et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation.2010; 122 (2): 156–163. DOI: 10.1161/CIRCULATIONAHA.109.911818.
(check this in PDF content)
37
Humbert M., Sitbon O., Yaici A. et al. Survival in incident and prevalent cohort of patients with pulmonary arterial hypertension. Eur. Respir. J.2010; 36 (3): 549–555. DOI: 10.1183/ 09031936.00057010.
(check this in PDF content)
38
Stenmark K.R., Davie N., Frid M. et al. Role of the adventitia in pulmonary vascular remodeling. Physiology(Bethesda). 2006; 21 (2): 134–145. DOI: 10.1152/physiol. 00053.2005.
(check this in PDF content)
39
Tuber R.M., Cool C.D., Yeager M. et al. The pathobiology of pulmonary hypertension. Endothelium. Clin. Chest Med.2001; 22 (3): 405–418.
(check this in PDF content)
40
Gossage J.R., Christman B.W. Mediators of acute and chronic pulmonary hypertension.Semin. Respir. Crit. Care Med. 1994; 15 (4): 453–462.
(check this in PDF content)
41
GaliéN., Manes A., Branzi A. New insights on pulmonary arterial hypertension. Rev. Esp. Cardiol.2004; 57 (7): 603– 607. DOI: 10.1016/S1885-5857(06)60282-X.
(check this in PDF content)
42
Duong-Quy S. Physiopathology of pulmonary hypertension: from bio-molecular mechanism to target treatment. J. Vasc. Med. Surg. 2016; 22 (4): 294–299. DOI: 10.4172/2329-6925. 1000294.
(check this in PDF content)
43
Duplain H., Burcelin R., Sartori C. et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation. 2001; 104 (3): 342–345. DOI: 10.1161/01.CIR.104.3.342.
(check this in PDF content)
44
Barst R.J., McGoon M., Torbicki A. et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.2004; 43 (12, Suppl.): S40–S47. DOI: 10.1016/ j.jacc.2004.02.032.
(check this in PDF content)
45
McGoon M.D. The assessment of pulmonary hypertension. Clin. Chest Med.2001; 22 (3): 493–508.
(check this in PDF content)
46
McLaughlin V.V., McGoon M.D. Pulmonary arterial hypertension. Circulation.2006; 114 (13): 1417–1431. DOI: 10.1161/ CIRCULATIONAHA.104.503540.
(check this in PDF content)
47
Trip P., Nossent E.J., de Man F.S. et al. Severely reduced diffusion capacity in idiopathic pulmonary arterial hypertension: patient characteristics and treatment responses. Eur. Respir. J. 2013; 42 (6): 1575–1585. DOI: 10.1183/ 09031936.00184412.
(check this in PDF content)
48
Sun X.G., Hansen J.E., Oudiz R.J., Wasserman K. Pulmonary function in primary pulmonary hypertension. J. Am. Coll. Cardiol.2003; 41 (6): 1028–1035. DOI: 10.1016/S0735-1097 (02)02964-9.
(check this in PDF content)
49
Чазова И.Е., Мартынюк Т.В., Авдеев С.Н. и др. Клинические рекомендации по диагностике и лечению легочной гипертензии. Терапевтический архив.2014; 86 (9): 4–23. DOI: terapevticheskij-arkhiv/2014/9/030040-3660201491.
(check this in PDF content)
50
Rudski L.G., Lai W.W., Afilalo J. et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J. Am. Soc. Echocardiogr. 2010; 23 (7): 685–713. DOI: 10.1016/j.echo. 2010. 05.010.
(check this in PDF content)
51
Lang R.M., Badano L.P., Mor-Avi V. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur. Heart J. Cardiovasc. Imaging.2015; 28 (1): 1–39. DOI: 10.1016/j.echo.2014. 10.003.
(check this in PDF content)
52
Lang I., Madani M. Update on Chronic Thromboembolic Pulmonary Hypertension. Circulation. 2014; 130 (6): 508– 518. DOI: 10.1161/CIRCULATIONAHA.114.009309.
(check this in PDF content)
53
Rajaram S., Swift A.J., Telfer A. et al. 3D contrast-enhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension: results from the ASPIRE Registry. Thorax. 2013; 68 (7): 677–678. DOI: org/ 10.1136/thoraxjnl-2012-203020.
(check this in PDF content)
54
Sitbon O., Badesch D., Channick R. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003; 124 (1): 247–254. DOI: 10.1378/chest.124.1_suppl. 247S.
(check this in PDF content)
55
Channick R.N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet. 2001; 358 (9288): 1119–1123. DOI: 10.1016/ S0140-6736(01)06250-X.
(check this in PDF content)
56
GaliéN., Rubin L., Hoeper M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet. 2008; 371 (2930): 2093–2100. DOI: 10. 1016/S0140-6736(08)60919-8.
(check this in PDF content)
57
Savarese G., Paolillo S., Costanzo P. et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. JACC. 2012; 60 (13): 1192–1201. DOI: 10. 1016/j.jacc.2012.01.083.
(check this in PDF content)
58
Barst R.J., Maislin G., Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999; 99 (9): 1197–1208. DOI: 10.1161/01.CIR.99.9.1197.
(check this in PDF content)
59
Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin. Chest Med. 2007; 28 (1): 117–125.
(check this in PDF content)
60
Мартынюк Т.В., Архипова О.А., Кобаль Е.А. и др. Применение неселективного антагониста рецепторов эндотелина бозентана у больных идиопатической легочной гиперЦарева Н.А.Идиопатическая легочная артериальная гипертензия: современный подход к диагностике и лекарственной терапии тензией: первый российский опыт и взгляд в будущее. Системные гипертензии.2011; 8 (4): 51–56.
(check this in PDF content)
61
Provencher S., Sitbon O., Humbert M. et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.Eur. Heart J. 2006; 27 (5): 589–595. DOI: 10.1093/eurheartj/ehi728.
(check this in PDF content)
62
Авдеев С.Н., Царева Н.А., Неклюдова Г.В., Чучалин А.Г. Первый клинический опыт применения антагониста рецепторов эндотелина бозентана у пациентов с легочной артериальной гипертензией: результаты 1-годичного исследования.Терапевтический архив. 2013; 85 (3): 38–43.
(check this in PDF content)
63
Rubin L., Badesch M., Barst R. et al. Randomized trial of endothelin antagonist therapy. N. Engl. J. Med. 2002; 346 (12): 896–903. DOI: 10.1056/NEJMoa012212.
(check this in PDF content)
64
GaliéN., Olschewski H., Oudiz R.J. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008; 117 (23): 3010–3019. DOI: 10.1161/CIRCULATIONAHA.107. 742510.
(check this in PDF content)
65
Oudiz R.J., GaliéN., Olschewski H. et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J. Am. Coll. Cardiol.2009; 52 (21): 1971–1981. DOI: 10.1016/j.jacc.2009.07.033.
(check this in PDF content)
66
Badesch D.B., Feldman J., Keogh A. et al. ARIES3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.Cardiovasc. Ther.2012; 30 (2): 93–99. DOI: 10.1111/j.1755-5922.2011.00279.x.
(check this in PDF content)
67
Pulido T., Adzerikho I., Channick R.N. et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N. Engl. J. Med.2013; 369 (9): 809–818. DOI: 10.1056/NEJ Moa1213917.
(check this in PDF content)
68
GaliéN., Manes A. New treatment strategies for pulmonary arterial hypertension: hopes or hypes? J. Am. Coll. Cardiol. 2013; 62 (12): 1101–1102. DOI: 10.1016/j.jacc.2013. 06.032.
(check this in PDF content)
69
Rubin L.J., Mendoza J., Hood M. et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann. Intern. Med.1990; 112 (7): 485–491.
(check this in PDF content)
70
Barst R.J., Rubin L.J., Long W.A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [see comments]. N. Engl. J. Med. 1996; 334 (5): 296–302. DOI: 10. 1056/NEJM199602013340504.
(check this in PDF content)
71
Sitbon O., Humbert M., Nunes H. et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 2002; 40 (4): 780–788. DOI: 10.1016/S0735-1097(02) 02012-0.
(check this in PDF content)
72
McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002; 106 (12): 1477–1482. DOI: 10.1161/01.CIR. 0000029100.82385.58.
(check this in PDF content)
73
Sitbon O., Delcroix M., Bergot E. et al. EPITOME-2: an openlabel study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. Am. Heart J.2014; 167 (2): 210–217. DOI: 10. 1016/j.ahj.2013.08.007.
(check this in PDF content)
74
GaliéN., Manes A., Branzi A. Prostanoids for pulmonary arterial hypertension.Am. J. Respir. Med.2003; 2 (2): 123–137.
(check this in PDF content)
75
Simonneau G., Barst R.J., GaliéN. et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med.2002; 165 (6): 800–804. DOI: 10.1164/ajrccm.165. 6.2106079.
(check this in PDF content)
76
Hiremath J., Thanikachalam S., Parikh K. et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J. Heart Lung Transplant. 2010; 29 (2): 137–149. DOI: 10.1016/j.healun.2009.09.005.
(check this in PDF content)
77
Tapson V.F., Gomberg-Maitland M., McLaughlin V.V. et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006; 129 (3): 683–688. DOI: 10.1378/chest. 129.3.683.
(check this in PDF content)
78
Barst R.J., McGoon M., McLaughlin V.V. et al. Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2003; 41 (12): 2119–2125. DOI: 10.1016/S0735-1097(03) 00463-7.
(check this in PDF content)
79
Olschewski H., Simommeau G., GaliéN. et al. Inhaled iloprost in severe pulmonary hypertension.N. Engl. Med. 2002; 347 (5): 322–329. DOI: 10.1056/NEJMoa020204.
(check this in PDF content)
80
McLaughlin V.V., Oudiz R.J., Frost A. et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.2006; 174 (11): 1257–1263. DOI: 10.1164/rccm.200603-358OC.
(check this in PDF content)
81
Ghofrani H.A., Rose F., Schermuly R.T. et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol.2003; 42 (1): 158–164. DOI: 10.1016/S0735-1097(03) 00555-2.
(check this in PDF content)
82
Michelakis E., Tymchak W., Lien D. et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002; 105 (20): 2398–2403. DOI: 10. 1161/01.CIR.0000016641.12984.DC.
(check this in PDF content)
83
Evgenov O.V., Pacher P., Schmidt P.M. et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov.2006; 5 (9): 755–768. DOI: 10.1038/nrd2038.
(check this in PDF content)
84
Schermuly R.T., Stasch J.P., Pullamsetti S.S. et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur. Respir. J.2008; 32 (4): 881–891. DOI: 10.1183/09031936.00114407.
(check this in PDF content)
85
Stasch J.P., Evgenov O.V. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb. Exp. Pharmacol. 2013; 218 (1): 279–313. DOI: 10.1007/978-3-642-38664-0_12.
(check this in PDF content)
86
Ghofrani H.A., Grimminger F. Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. Eur. Respir. Rev.2009; 18 (111): 35–41. DOI: 10.1183/ 09059180.00011112.
(check this in PDF content)
87
Stasch J.P., Hobbs A. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb. Exp. Pharmacol. 2009; (191): 277–308. DOI: 10.1007/978-3-540-68964-5_13.
(check this in PDF content)
88
Ghofrani H.A., GaliéN., Grimminger F. et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2013; 369 (4): 330–340. DOI: 10.1056/NEJMoa 1209655.
(check this in PDF content)
89
Ghofrani H.A., D'Armini A., Grimminger F. et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med.2013; 369 (4): 319–329. DOI: 10.1056/ NEJMoa1209657.
(check this in PDF content)
90
Царева Н.А., Авдеев С.Н., Неклюдова Г.В. Последовательная комбинированная терапия у больной идиопатической легочной артериальной гипертензией. Кардиология.2016; 56 (3): 97–100. DOI: 10.18565/cardio.2016.3.97-100.
(check this in PDF content)
91
McLaughlin V.V., Channik R., Chin K.M. et al. Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study. J. Am. Coll. Cardiol.2015; 65 (10): 1538–1588. DOI: 10.1016/S0735-1097(15)61538-8. Поступила 21.02.17
(check this in PDF content)